A new study shows that African American women coinfected with human immunodeficiency virus (HIV) and hepatitis C virus (HCV) are less likely to die from liver disease than Caucasian or Hispanic women. Findings in the November issue of Hepatology, a journal published by Wiley on behalf of the American Association for the Study of Liver Diseases, indicate that lower liver-related mortality in African American women was independent of other causes of death.
Medical evidence reports that nearly five million Americans are infected with HCV, with 80% having active virus in their blood (viremia). Moreover, prior research found that one third of those with HIV are co-infected with HCV—the second leading cause of death among those with HIV. Studies also show that while HCV clearance (elimination of the virus spontaneously or with treatment) is lower among African Americans, once chronically infected this group seems to develop less fibrosis and liver inflammation compared to other racial groups.
Despite much study on racial differences in hepatitis C development, it remains unclear how race impacts liver-related death in those with HCV or HIV/HCV co-infection, said Dr. Monika Sarkar from the University of California, San Francisco and lead author of the current study examining racial differences and mortality among women with HIV and HCV.
The UCSF team followed 794 subjects who were part of the Womens Interagency HIV study, which was funded by the National Institutes of Health (NIH). Those women in the follow-up study included 140 Caucasians (62%), 159 Hispanics (20%), and 495 African Americans (18%). Study participants were seen twice each year to have detailed health histories, physical exams, interviews, and clinical testing.
During a median follow-up of nearly 9 years, researchers documented 438 deaths; 37% from HIV/AIDS and 11% due to liver-related disease. Nearly 56% of African Americans, 56% of Caucasians and 52% of Hispanics died during follow-up. The team reports that liver disease was the primary cause of death in 21% of Hispanics, 14% of Caucasians, and only 8% of African Americans.
Our findings indicate that the number of African American women co-infected with HIV/HCV who died from liver disease was significantly lower than Caucasian and Hispanic women with the same diseases, concludes Dr. Sarkar. Further studies are needed to understand the reasons for such a discrepancy in liver-related mortality among these racial groups.
This study is published in Hepatology. Media wishing to receive a PDF of this article may contact firstname.lastname@example.org.
Full citation: Lower Liver-Related Death in African American Women with HIV/HCV Co-Infection Compared to Caucasian and Hispanic Women. Monika Sarkar, Peter Bacchetti, Audrey L French, Phyllis Tien, Marshall J Glesby, Marek Nowicki, Michael Plankey, Stephen Gange, Gerald Sharp, Howard Minkoff and Marion G Peters for the Womens Interagency HIV Study (WIHS). Hepatology; (DOI: 10.1002/hep.25859); Print Issue Date: November, 2012.
About the Journal
Hepatology is the premier publication in the field of liver disease, publishing original, peer-reviewed articles concerning all aspects of liver structure, function and disease. Each month, the distinguished Editorial Board monitors and selects only the best articles on subjects such as immunology, chronic hepatitis, viral hepatitis, cirrhosis, genetic and metabolic liver diseases and their complications, liver cancer, and drug metabolism. Hepatology is published on is published by Wiley on behalf of the American Association for the Study of Liver Diseases (AASLD). For more information, please visit http://wileyonlinelibrary.com/journal/hep.
Founded in 1807, John Wiley & Sons, Inc. has been a valued source of information and understanding for more than 200 years, helping people around the world meet their needs and fulfill their aspirations. Wiley and its acquired companies have published the works of more than 450 Nobel laureates in all categories: Literature, Economics, Physiology or Medicine, Physics, Chemistry, and Peace.
Wiley is a global provider of content and content-enabled workflow solutions in areas of scientific, technical, medical, and scholarly research; professional development; and education. Our core businesses produce scientific, technical, medical, and scholarly journals, reference works, books, database services, and advertising; professional books, subscription products, certification and training services and online applications; and education content and services including integrated online teaching and learning resources for undergraduate and graduate students and lifelong learners. Wileys global headquarters are located in Hoboken, New Jersey, with operations in the U.S., Europe, Asia, Canada, and Australia. The Companys Web site can be accessed at http://www.wiley.com. The Company is listed on the New York Stock Exchange under the symbols JWa and JWb.
What: The 63rd Annual Meeting of the American Association for the Study of Liver Diseases (AASLD)
Founded in 1950, AASLD is the leading organization of scientists and healthcare professionals committed to preventing and curing liver disease. AASLD has grown into an international society responsible for all aspects of hepatology, and the annual meeting attracts 8,500 physicians, surgeons, researchers, and allied health professionals from around the world.
The Liver Meeting® is the premier meeting in the science and practice of hepatology, including the latest findings on new drugs, novel treatments, and the results from pilot and multicenter studies.
When: November 9-13, 2012
Where: Hynes Convention Center in Boston, Massachusetts
Contact: Please visit http://www.aasld.org/lm2012/2012/press/Pages/default.aspx to obtain a press pass for this event.